Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.

ABSTRACT:

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC6394110 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature